What has prevented the expansion of insulin sensitisers?

Expert Opinion on Investigational Drugs
Jerry R Colca, Rolf F Kletzien

Abstract

The ability to improve insulin sensitivity with synthetic compounds was uncovered by empirical discoveries by Takeda in the late 1970s. The potential of a class of thiazolidinediones for the treatment of Type 2 diabetes, by decreasing glucose and triglycerides alongside lowering circulating insulin, was made public during the 1980s. As the first of the chemicals (pioglitazone, troglitazone and rosliglitazone) proceeded to clinical trials, these observations were soon extended to demonstrate a rich and complex pharmacology. The promise of this mode of action included prevention of diabetes as well as making a significant impact on the incidence and severity of the life-shortening consequences of the established disease. There are now two of these drugs on the market: pioglitazone and rosiglitazone, and they are being used to treat significant numbers of diabetic patients. However, the use of these drugs and development of future generations of successful candidates has not met the expectations that were held out in the early 1980s. This can be attributed to two major prevailing conditions. Troglitazone became the first thiazolidinedione to be approved as a result of delays in the development of pioglitazone. Unfortunately, trogl...Continue Reading

References

Aug 1, 1992·Diabetes Care·C A Hofmann, J R Colca
Sep 1, 1995·Metabolism: Clinical and Experimental·M K Lee, J M Olefsky
Feb 12, 1998·The Journal of Clinical Investigation·C F BurantR A Graves
Jan 14, 1999·The American Journal of Physiology·N B RudermanL A Witters
Oct 24, 2000·Trends in Endocrinology and Metabolism : TEM·J M Olefsky, A R Saltiel
Nov 22, 2002·Current Medical Research and Opinion·Kathy Ann LaCivita, Gustavo Villarreal
Dec 18, 2002·The Journal of Biological Chemistry·Cinzia Dello RussoDouglas L Feinstein
Jan 17, 2003·Molecular and Cellular Biology·Leanne Wilson-FritchSilvia Corvera
Jan 31, 2003·American Journal of Physiology. Endocrinology and Metabolism·Philip D G MilesJerrold M Olefsky
May 6, 2003·The Journal of Pharmacology and Experimental Therapeutics·Parimal MisraRajagopalan Ramanujam
Oct 23, 2003·American Journal of Physiology. Endocrinology and Metabolism·Jerry R ColcaW Rodney Mathews
Dec 9, 2003·Proceedings of the National Academy of Sciences of the United States of America·Weimin HeRonald M Evans
Jul 6, 2004·American Journal of Hypertension·Faina SchwartzHaralambos Gavras
Oct 23, 2004·Science·Frederick H WilsonRichard P Lifton
Dec 24, 2004·Diabetes·Vladimir B RitovDavid E Kelley
Jun 16, 2005·Proceedings of the National Academy of Sciences of the United States of America·Hui ZhangTianxin Yang
Oct 22, 2005·JAMA : the Journal of the American Medical Association·Steven E NissenEric J Topol

❮ Previous
Next ❯

Citations

Sep 4, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jinzhong LinJinfeng Wang
Jul 27, 2011·Proceedings of the National Academy of Sciences of the United States of America·John A ZurisRachel Nechushtai
Mar 21, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ajit S DivakaruniAnne N Murphy
Feb 22, 2012·The Journal of Biological Chemistry·John A ZurisPatricia A Jennings
Feb 7, 2009·International Journal of Clinical Practice·J Philippe, D Raccah
Sep 4, 2007·Proceedings of the National Academy of Sciences of the United States of America·Mark L PaddockPatricia A Jennings
Aug 19, 2006·Expert Opinion on Investigational Drugs·Jerry Colca
Jan 25, 2007·Expert Opinion on Investigational Drugs·Jerry R Colca
Oct 10, 2007·Expert Opinion on Investigational Drugs·Jerry R Colca
Oct 10, 2007·Expert Opinion on Investigational Drugs·Jerry R Colca
Oct 19, 2006·Expert Opinion on Drug Safety·Andrew J Krentz
Oct 20, 2015·Expert Opinion on Drug Discovery·Jerry R Colca
Oct 1, 2013·Expert Opinion on Investigational Drugs·Jerry R ColcaRolf F Kletzien
Apr 7, 2010·Expert Opinion on Investigational Drugs·Lalit S DoshiKumar V S Nemmani
Jun 28, 2007·Expert Opinion on Investigational Drugs·Katherine L Schaefer
Jul 27, 2010·Advanced Drug Delivery Reviews·Ira G Schulman
Apr 30, 2014·Diabetes, Obesity & Metabolism·J R ColcaR F Kletzien
Jun 29, 2018·Expert Opinion on Investigational Drugs·Jerry R ColcaWade J Adams
Aug 26, 2014·Molecular Endocrinology·Matthew B WrightMartin Bopst
Mar 7, 2013·Clinical Pharmacology and Therapeutics·J R ColcaD G Orloff

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.